Relay TherapeuticsRLAY
About: Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Employees: 294
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
121% more call options, than puts
Call options by funds: $758K | Put options by funds: $343K
67% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 5 (+2) [Q3]
56% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 45
52% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 31
33% more capital invested
Capital invested by funds: $843M [Q2] → $1.12B (+$274M) [Q3]
9% more funds holding
Funds holding: 177 [Q2] → 193 (+16) [Q3]
0.21% less ownership
Funds ownership: 97.42% [Q2] → 97.21% (-0.21%) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
JMP Securities Silvan Tuerkcan 35% 1-year accuracy 18 / 51 met price target | 405%upside $21 | Market Outperform Reiterated | 12 Dec 2024 |
HC Wainwright & Co. Robert Burns 23% 1-year accuracy 36 / 155 met price target | 285%upside $16 | Buy Maintained | 4 Dec 2024 |
Leerink Partners Christopher Liu 0% 1-year accuracy 0 / 1 met price target | 333%upside $18 | Outperform Maintained | 4 Dec 2024 |
Financial journalist opinion
Based on 6 articles about RLAY published over the past 30 days
